JSPR - Jasper Therapeutics, Inc. Stock Price, Fair Value and News

$21.57+0.04 (+0.19%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

JSPR Price Action

Last 7 days

4.7%

Last 30 days

2.8%

Last 90 days

-9.7%

Trailing 12 Months

288.0%

JSPR RSI Chart

JSPR Valuation

Market Cap

323.6M

Price/Earnings (Trailing)

-5.09

Price/Sales (Trailing)

84.92

EV/EBITDA

-104.95

Price/Free Cashflow

-5.58

JSPR Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

JSPR Fundamentals

JSPR Revenue

Revenue (TTM)

4.0M

Rev. Growth (Yr)

26.46%

Rev. Growth (Qtr)

-3.48%

JSPR Earnings

Earnings (TTM)

-63.5M

Earnings Growth (Yr)

-6.23%

Earnings Growth (Qtr)

-27.8%

JSPR Profitability

EBT Margin

-86.28%

Return on Equity

-75.92%

Return on Assets

-63.9%

Free Cashflow Yield

-17.91%

JSPR Investor Care

Shares Dilution (1Y)

46.57%

Diluted EPS (TTM)

-4.74

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	4.0M	0	0	0
2023	0	0	0	0
2022	0	0	0	0
2019	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Jasper Therapeutics, Inc.

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.

CEO	Mr. Ronald A. Martell
WEBSITE	jaspertherapeutics.com/
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	35

Jasper Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Jasper Therapeutics, Inc.? What does JSPR stand for in stocks?

JSPR is the stock ticker symbol of Jasper Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Jasper Therapeutics, Inc. (JSPR)?

As of Fri Dec 20 2024, market cap of Jasper Therapeutics, Inc. is 323.58 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of JSPR stock?

You can check JSPR's fair value in chart for subscribers.

Is Jasper Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether JSPR is over valued or under valued. Whether Jasper Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Jasper Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for JSPR.

What is Jasper Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, JSPR's PE ratio (Price to Earnings) is -5.09 and Price to Sales (PS) ratio is 84.92. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. JSPR PE ratio will change depending on the future growth rate expectations of investors.